Drug Trial Radar · NCT00430248
Efficacy and Safety of Oral Febuxostat in Participants With Gout
Last checked: Nov 20, 2026Latest source record: Feb 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,269
Actual
Start
Feb 2007
Primary completion
Mar 2008
Study completion Mar 2008
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Feb 1, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.
Conditions
- Gout
Interventions
FebuxostatDrug
Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
FebuxostatDrug
Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
AllopurinolDrug
Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months. Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.Time frame: Last Visit on treatment (up to 6 months)
Locations
258 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Hoover, Alabama
Site not named
Hueytown, Alabama
Site not named
Huntsville, Alabama
Site not named
Mobile, Alabama
Site not named
Montgomery, Alabama
Site not named
Northport, Alabama
Site not named
Ozark, Alabama
Site not named
Tuscaloosa, Alabama
Site not named
Chandler, Arizona
Site not named
Gilbert, Arizona
Site not named
Mesa, Arizona
Site not named
Peoria, Arizona
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Sierra Vista, Arizona
Site not named
Tucson, Arizona
Site not named
Fort Smith, Arkansas
Site not named
Jonesboro, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Carmichael, California
Site not named
Clovis, California
Site not named
Concord, California
Site not named
El Centro, California
Site not named
Fair Oaks, California
Site not named
Fullerton, California
Site not named
Huntington Beach, California
Site not named
Irvine, California
Site not named
La Jolla, California
Site not named
Laguna Hills, California
Site not named
Los Angeles, California
Site not named
Pasadena, California
Site not named
Rancho Cucamonga, California
Site not named
Riverside, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Luis Obispo, California
Site not named
Santa Barbara, California
Site not named
Santa Maria, California
Showing 40 of 258 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.